Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/17/2019 |
| Start Date: | May 26, 2017 |
| End Date: | January 18, 2021 |
An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)
A study to evaluate the safety of Nivolumab in patients with advanced or metastatic non-small
cell lung cancer
cell lung cancer
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Non small cell lung cancer (Squamous or non-squamous)
- At least one prior anti-cancer therapy that did not work
- ECOG Performance Scale 0-1
Exclusion Criteria:
- Cancer that has spread to the brain or leptomeninges unless there is no evidence of
progression by MRI for 8 weeks after treatment is complete and within 28 days before
first dose of study drug
- Active, known or suspected autoimmune disease or infection
- Prior immuno-oncology therapy
- Corticosteroids within 2 weeks of study drug administration
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials